PD-1/PD-L1 Pathway in Breast Cancer

Publisher： Karger

E-ISSN： 2296-5262|40|5|294-297

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.40, Iss.5, 2017-03, pp. : 294-297

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recent Insight into the Role of the PD‐1/PD‐L1 Pathway in Feto‐Maternal Tolerance and Pregnancy

By  

AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (ELECTRONIC), Vol. 74, Iss. 3, 2015-09 ,pp. : 201-208

John Wiley & Sons Inc

Access to resources Recommend Favorite

Therapeutic Intervention in Cancer and Chronic Viral Infections: Antibody Mediated Manipulation of PD-1/PD-L1 Interaction

By  

Reviews on Recent Clinical Trials, Vol. 7, Iss. 1, 2012-02 ,pp. : 10-23

Bentham Science Publishers

Access to resources Recommend Favorite

Comparison of the toxicity profile of PD‐1 versus PD‐L1 inhibitors in non–small cell lung cancer: A systematic analysis of the literature

By  

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 271-277

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer

By  

Oncology, Vol. 92, Iss. 5, 2017-02 ,pp. : 283-290

Karger

Access to resources Recommend Favorite

Interlaboratory concordance of PD‐L1 immunohistochemistry for non‐small‐cell lung cancer

By  

HISTOPATHOLOGY, Vol. 72, Iss. 3, 2018-02 ,pp. : 449-459

John Wiley & Sons Inc

Access to resources Recommend Favorite